Keywords: Otsuka, Delamanid, Ph IIb, Tuberculosis

Positive Ph IIb results for Otsuka TB drug candidate delamanid

Article | 07 June 2012

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) has announced Phase IIb clinical trial results on the safety and efficacy of delamanid, the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Otsuka

Go to company listing

Related Drugs

delamanid

Go to drug listing